StockMacro
Company, fund or insider

Help

Menu

MiMedx

$3.05 -17% in 6 monthsMarket cap $445.1M

MDXG on XNAS, Health Care, MiMedx Group, Inc, job postings

Measures activity, not value. Not investment advice.

Latest quarter revenue fell 45% to $62.3M and the stock is down 53% in a year.

  • BadTwelve month revenue fell 23% to $303.7M, with a $19.2M net loss

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.

Industry
Surgical & medical instruments & apparatus (Health Care)
Employees
808
Website
mimedx.com
Listed
Nasdaq, US
Last results
28 Oct 2026
Next results
expected around 24 Feb 2027 (an estimate: a year ago it reported on 25 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $62.3M, net loss $8.7M.
Quarter to 31 Dec 2021: revenue $67.4M, net income $2.2MQuarter to 31 Dec 2021: revenue $67.4M, net income $2.2MQuarter to 31 Mar 2022: revenue $58.9M, net income -$10.5MQuarter to 31 Mar 2022: revenue $58.9M, net income -$10.5MQuarter to 30 Jun 2022: revenue $66.9M, net income -$10.9MQuarter to 30 Jun 2022: revenue $66.9M, net income -$10.9MQuarter to 30 Sep 2022: revenue $67.7M, net income -$8.4MQuarter to 30 Sep 2022: revenue $67.7M, net income -$8.4MQuarter to 31 Dec 2022: revenue $74.4M, net income -$414KQuarter to 31 Dec 2022: revenue $74.4M, net income -$414KQuarter to 31 Mar 2023: revenue $71.7M, net income -$5.0MQuarter to 31 Mar 2023: revenue $71.7M, net income -$5.0MQuarter to 30 Jun 2023: revenue $81.3M, net income $1.2MQuarter to 30 Jun 2023: revenue $81.3M, net income $1.2MQuarter to 30 Sep 2023: revenue $81.7M, net income $8.5MQuarter to 30 Sep 2023: revenue $81.7M, net income $8.5MQuarter to 31 Dec 2023: revenue –, net income $53.5MQuarter to 31 Mar 2024: revenue $84.7M, net income $9.3MQuarter to 31 Mar 2024: revenue $84.7M, net income $9.3MQuarter to 30 Jun 2024: revenue $87.2M, net income $17.6MQuarter to 30 Jun 2024: revenue $87.2M, net income $17.6MQuarter to 30 Sep 2024: revenue $84.1M, net income $8.1MQuarter to 30 Sep 2024: revenue $84.1M, net income $8.1MQuarter to 31 Dec 2024: revenue $92.9M, net income $7.4MQuarter to 31 Dec 2024: revenue $92.9M, net income $7.4MQuarter to 31 Mar 2025: revenue $88.2M, net income $7.0MQuarter to 31 Mar 2025: revenue $88.2M, net income $7.0MQuarter to 30 Jun 2025: revenue $98.6M, net income $9.6MQuarter to 30 Jun 2025: revenue $98.6M, net income $9.6MQuarter to 30 Sep 2025: revenue $113.7M, net income $16.7MQuarter to 30 Sep 2025: revenue $113.7M, net income $16.7MQuarter to 31 Dec 2025: revenue $118.1M, net income $15.2MQuarter to 31 Dec 2025: revenue $118.1M, net income $15.2MQuarter to 31 Mar 2026: revenue $59.0M, net income -$10.9MQuarter to 31 Mar 2026: revenue $59.0M, net income -$10.9MQuarter to 30 Jun 2026: revenue $64.4M, net income -$14.8MQuarter to 30 Jun 2026: revenue $64.4M, net income -$14.8MQuarter to 30 Sep 2026: revenue $62.3M, net income -$8.7MQuarter to 30 Sep 2026: revenue $62.3M, net income -$8.7M
31 Dec 2021RevenueNet incomeNet losstallest bar $118.1M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$62.3M-$8.7M
30 Jun 2026$64.4M-$14.8M
31 Mar 2026$59.0M-$10.9M
31 Dec 2025$118.1M$15.2M
30 Sep 2025$113.7M$16.7M
30 Jun 2025$98.6M$9.6M
31 Mar 2025$88.2M$7.0M
31 Dec 2024$92.9M$7.4M
30 Sep 2024$84.1M$8.1M
30 Jun 2024$87.2M$17.6M
31 Mar 2024$84.7M$9.3M
31 Dec 2023–$53.5M
30 Sep 2023$81.7M$8.5M
30 Jun 2023$81.3M$1.2M
31 Mar 2023$71.7M-$5.0M
31 Dec 2022$74.4M-$414K
30 Sep 2022$67.7M-$8.4M
30 Jun 2022$66.9M-$10.9M
31 Mar 2022$58.9M-$10.5M
31 Dec 2021$67.4M$2.2M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $303.7M $393.4M
Revenue growthRevenue of the last 12 months compared with the 12 months before. -23% +13%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$19.2M $40.8M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$0.13 $0.27
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 77.3% 82.0% 60.5%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. -8.3% 13.7% -8.3%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -6.3% 10.4% -10.1%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -8.5% -26.3%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $120.8M $142.1M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. – $18.2M
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). – -$123.9M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.31
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $1.45
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 28.0
P/SPrice to sales: market cap divided by revenue of the last 12 months. 1.5 2.3
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 2.5
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 2.1 2.8

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
MiMedxMDXG (this company) $445.1Mloss1.5-23%-6.3%
AngioDynamicsANGO $454.6Mloss1.4+8.2%-10.1%
Shoulder InnovationsSI $421.6Mloss6.5+55%-51.7%
CarlsmedCARL $477.4Mloss6.7+60%-55.8%
Avita MedicalRCEL $495.0Mloss5.8+17%-42.7%
Mobia MedicalMOBI $394.5M––––

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

-45%

$62.3M vs $113.7M (quarter ended 30 Sep 2026)

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

-4.5%

214 13F filers vs 224

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

79%

115.2M shares held by 13F filers (30 Sep 2026) of 145.9M outstanding (22 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

6.1%

9.0M shares sold short (30 Oct 2026) of 145.9M outstanding (22 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

4.3

9.0M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-3.2%

9.3M shares sold short in the report before, 9.0M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

49%

49% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 46%

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$200K

4 quarters

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

7

7 articles in the last 7 days; its usual week has 0.5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

–

7 articles in the last 7 days; its usual week has 0.5: fewer than one, so there is nothing to compare with.

Price $3.05 on 20 Nov 2026, -53% over 12 months (12-month range $3.05 to $7.25)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders bought a net $0 in the last 12 months (the 12 months before: -$803K).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 0 published in the last 12 months, -100% on the 12 months before.
Revenue per quarter. Revenue $62.3M in the latest quarter, -45% on a year earlier.
Capital spending per quarter. Capital spending $427K in the latest quarter, -36% on a year earlier.
Institutional holders (13F filers). 214 13F filers reported holding it in the latest 13F quarter, -2.3% on a year earlier.
Federal obligations. Federal obligations: $0 published in the last 12 months.
Lobbying spend. Lobbying spend: $200K published in the last 12 months, 0% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
12 May 2026Sharp changeShort interest spike: short interest spike, 8.4M vs usual 5.1M (2026-04-30); 1.8x the same period a year earlier
30 Apr 2026Sharp changeQuarterly revenue change: quarterly revenue change, 59.0M vs usual 90.6M (2026-03-31); 0.7x the same period a year earlier
28 Apr 2026Sharp changeShort interest spike: short interest spike, 7.4M vs usual 5.0M (2026-04-15); 1.5x the same period a year earlier
16 Apr 20268-K and other filingsDirector or officer change
16 Apr 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
14 Apr 2026Sharp changeShort interest spike: short interest spike, 7.7M vs usual 5.0M (2026-03-31); 1.6x the same period a year earlier
17 Mar 2026Sharp changeShort interest spike: short interest spike, 6.7M vs usual 4.9M (2026-02-27); 1.6x the same period a year earlier
3 Mar 2026Sharp changeShort interest spike: short interest spike, 7.3M vs usual 4.8M (2026-02-13); 2.0x the same period a year earlier
26 Feb 2026Sharp changeQuarterly revenue change: quarterly revenue change, 118.1M vs usual 87.7M (2025-12-31); 1.3x the same period a year earlier
17 Feb 2026Sharp changeShort interest spike: short interest spike, 7.1M vs usual 4.8M (2026-01-30); 1.8x the same period a year earlier
30 Oct 2025Sharp changeQuarterly revenue change: quarterly revenue change, 113.7M vs usual 87.0M (2025-09-30); 1.4x the same period a year earlier
24 Jul 2024Lobbying filingnew lobbying registration (ARMORY HILL ADVOCATES (FORMERLY KNOWN AS RAWLSON POLICY GROUP))
2 Apr 2024Sharp changeShort interest spike: short interest spike, 5.5M vs usual 3.5M (2024-03-15); 1.7x the same period a year earlier
12 Mar 2024Sharp changeShort interest spike: short interest spike, 5.3M vs usual 3.5M (2024-02-29); 1.7x the same period a year earlier
5 Mar 2024Sharp changeShort interest spike: short interest spike, 4.9M vs usual 3.4M (2024-02-15); 1.6x the same period a year earlier
4 Mar 20248-K and other filingsDirector or officer change
4 Mar 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
22 Jan 20248-K and other filingsA major agreement ended
14 Nov 2023Sharp changeShort interest spike: short interest spike, 4.7M vs usual 3.3M (2023-10-31); 1.3x the same period a year earlier
31 Oct 2023Sharp changeShort interest spike: short interest spike, 4.7M vs usual 3.3M (2023-10-13); 1.2x the same period a year earlier
17 Oct 2023Sharp changeShort interest spike: short interest spike, 4.6M vs usual 3.3M (2023-09-29); 1.1x the same period a year earlier
5 Sep 20238-K and other filingsDirector or officer change
5 Jul 20238-K and other filingsDirector or officer change
20 Jun 20238-K and other filingsDirector or officer change
14 Jun 20238-K and other filingsDirector or officer change
24 Mar 20238-K and other filingsDirector or officer change
30 Jan 20238-K and other filingsDirector or officer change
3 Jan 20238-K and other filingsDirector or officer change
16 Dec 20228-K and other filingsDirector or officer change
16 Dec 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
16 Sep 20228-K and other filingsDirector or officer change
6 Sep 20228-K and other filingsDirector or officer change
13 Jun 20228-K and other filingsDirector or officer change
13 Jun 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Feb 2022: -$348K published
Month from 1 Mar 2022: -$577K published
Month from 1 May 2022: -$57K published
Month from 1 Jun 2022: -$420K published
Month from 1 Jul 2022: -$51K published
Month from 1 Aug 2022: -$157K published
Month from 1 Sep 2022: -$94K published
Month from 1 Dec 2022: -$14K published
Month from 1 Feb 2023: -$156K published
Month from 1 Mar 2023: -$166K published
Month from 1 Apr 2023: -$139K published
Month from 1 May 2023: -$495K published
Month from 1 Jun 2023: $640K published
Month from 1 Nov 2023: $36K published
Month from 1 Feb 2024: -$497K published
Month from 1 Mar 2024: -$162K published
Month from 1 Feb 2025: -$509K published
Month from 1 Mar 2025: -$1.1M published
Month from 1 May 2025: $1.3M published
Month from 1 Nov 2025: -$433K published
H-1B/E-3 applications certified
Quarter from 1 Jul 2023: 1 published
Quarter from 1 Jul 2024: 2 published
Quarter from 1 Jul 2025: 1 published
Revenue per quarter
Quarter ended 31 Dec 2021: $67.4M, -1.7% on a year earlier; public on 1 Mar 2022
Quarter ended 31 Mar 2022: $58.9M, -1.8% on a year earlier; public on 4 May 2022
Quarter ended 30 Jun 2022: $66.9M, -1.9% on a year earlier; public on 3 Aug 2022
Quarter ended 30 Sep 2022: $67.7M, +7.3% on a year earlier; public on 3 Nov 2022
Quarter ended 31 Dec 2022: $74.4M, +10% on a year earlier; public on 1 Mar 2023
Quarter ended 31 Mar 2023: $71.7M, +22% on a year earlier; public on 3 May 2023
Quarter ended 30 Jun 2023: $81.3M, +21% on a year earlier; public on 2 Aug 2023
Quarter ended 30 Sep 2023: $81.7M, +21% on a year earlier; public on 31 Oct 2023
Quarter ended 31 Mar 2024: $84.7M, +18% on a year earlier; public on 1 May 2024
Quarter ended 30 Jun 2024: $87.2M, +7.3% on a year earlier; public on 1 Aug 2024
Quarter ended 30 Sep 2024: $84.1M, +2.9% on a year earlier; public on 31 Oct 2024
Quarter ended 31 Dec 2024: $92.9M; public on 27 Feb 2025
Quarter ended 31 Mar 2025: $88.2M, +4.1% on a year earlier; public on 1 May 2025
Quarter ended 30 Jun 2025: $98.6M, +13% on a year earlier; public on 31 Jul 2025
Quarter ended 30 Sep 2025: $113.7M, +35% on a year earlier; public on 30 Oct 2025
Quarter ended 31 Dec 2025: $118.1M, +27% on a year earlier; public on 26 Feb 2026
Quarter ended 31 Mar 2026: $59.0M, -33% on a year earlier; public on 30 Apr 2026
Quarter ended 30 Jun 2026: $64.4M, -35% on a year earlier; public on 30 Jul 2026
Quarter ended 30 Sep 2026: $62.3M, -45% on a year earlier; public on 29 Oct 2026
Capital spending per quarter
Quarter ended 31 Mar 2021: $1.9M; public on 4 May 2022
Quarter ended 30 Jun 2021: $405K; public on 3 Aug 2022
Quarter ended 30 Sep 2021: $547K; public on 3 Nov 2022
Quarter ended 31 Dec 2021: $325K; public on 29 Feb 2024
Quarter ended 31 Mar 2022: $118K, -94% on a year earlier; public on 4 May 2022
Quarter ended 30 Jun 2022: $380K, -6.2% on a year earlier; public on 3 Aug 2022
Quarter ended 30 Sep 2022: $349K, -36% on a year earlier; public on 3 Nov 2022
Quarter ended 31 Dec 2022: $667K, +105% on a year earlier; public on 29 Feb 2024
Quarter ended 31 Mar 2023: $633K, +436% on a year earlier; public on 3 May 2023
Quarter ended 30 Jun 2023: $299K, -21% on a year earlier; public on 2 Aug 2023
Quarter ended 30 Sep 2023: $628K, +80% on a year earlier; public on 31 Oct 2023
Quarter ended 31 Dec 2023: $427K, -36% on a year earlier; public on 29 Feb 2024
Institutional holders (13F filers)
31 Dec 2021 report: 136; public on 14 Feb 2022
31 Mar 2022 report: 139; public on 16 May 2022
30 Jun 2022 report: 145; public on 15 Aug 2022
30 Sep 2022 report: 131; public on 14 Nov 2022
31 Dec 2022 report: 138; public on 14 Feb 2023
31 Mar 2023 report: 154; public on 15 May 2023
30 Jun 2023 report: 166; public on 14 Aug 2023
30 Sep 2023 report: 173; public on 14 Nov 2023
31 Dec 2023 report: 189; public on 14 Feb 2024
31 Mar 2024 report: 195; public on 15 May 2024
30 Jun 2024 report: 189; public on 14 Aug 2024
30 Sep 2024 report: 185; public on 14 Nov 2024
31 Dec 2024 report: 207; public on 14 Feb 2025
31 Mar 2025 report: 209; public on 15 May 2025
30 Jun 2025 report: 206; public on 14 Aug 2025
30 Sep 2025 report: 219; public on 14 Nov 2025
31 Dec 2025 report: 222; public on 17 Feb 2026
31 Mar 2026 report: 232; public on 15 May 2026
30 Jun 2026 report: 224; public on 14 Aug 2026
30 Sep 2026 report: 214; public on 16 Nov 2026
Federal obligations
Month from 1 Jan 2022: -$1.0 published
Month from 1 Feb 2022: $0 published
Month from 1 Aug 2022: $22K published
Month from 1 Oct 2022: -$2K published
Month from 1 Dec 2022: -$720 published
Month from 1 Jan 2023: $20K published
Month from 1 Feb 2023: $67K published
Month from 1 Mar 2023: $740 published
Month from 1 Apr 2023: $10K published
Month from 1 Nov 2023: $2K published
Month from 1 Sep 2024: $15K published
Month from 1 Nov 2024: $10K published
Month from 1 Feb 2025: -$2K published
Lobbying spend
Quarter from 1 Jan 2022: $30K published
Quarter from 1 Apr 2022: $30K published
Quarter from 1 Jul 2022: $50K published
Quarter from 1 Oct 2022: $50K published
Quarter from 1 Jan 2023: $50K published
Quarter from 1 Apr 2023: $50K published
Quarter from 1 Jul 2023: $50K published
Quarter from 1 Oct 2023: $20K published
Quarter from 1 Jan 2024: $20K published
Quarter from 1 Apr 2024: $20K published
Quarter from 1 Jul 2024: $50K published
Quarter from 1 Oct 2024: $50K published
Quarter from 1 Jan 2025: $50K published
Quarter from 1 Apr 2025: $50K published
Quarter from 1 Jul 2025: $50K published
Quarter from 1 Oct 2025: $50K published
Quarter from 1 Jan 2026: $50K published
Quarter from 1 Apr 2026: $50K published
Quarter from 1 Jul 2026: $50K published
Quarter from 1 Oct 2026: $50K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market selling (USD, Form 4) at $433K (10 Nov 2025), 3.5× its normal reading; higher than 85% of its own history.
  • Insider net buying (open market): Insiders bought a net $0 in the last 12 months (the 12 months before: -$803K).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 0 published in the last 12 months, -100% on the 12 months before.
  • Revenue per quarter: Revenue $62.3M in the latest quarter, -45% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 72 insider trades

No trades in the last 90 days; the latest was filed 10 Nov 2025. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
10 Nov 2025Kimberly Maersk-MollerChief Commercial OfficerSell58,300$7.42$433KForm 4
5 May 2025Joseph H CapperChief Executive OfficerBuy200,000$6.34$1.3MForm 4
20 Mar 2025Kimberly Maersk-MollerChief Commercial OfficerSell1,759$8.04$14KForm 4
14 Mar 2025William Frank Hulse IVGeneral Counsel and CAOSell54,596$7.89$431KForm 4
14 Mar 2025Kimberly Maersk-MollerChief Commercial OfficerSell4,106$7.89$32KForm 4
12 Mar 2025William Frank Hulse IVGeneral Counsel and CAOSell81,446$7.80$635KForm 4
5 Mar 2025Kimberly Maersk-MollerChief Commercial OfficerSell2,111$8.41$18KForm 4
18 Feb 2025Ricci S WhitlowChief Operating OfficerSell61,420$8.28$509KForm 4

214 institutions reported shares at the end of Q3 2026, 79% of the shares outstanding; 26 opened a position, 32 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Essex Woodlands Management, Inc.28.2M19.3%$131.4MNo change
BlackRock, Inc.13.0M8.91%$60.6M+853K+7.0%
Trigran Investments, Inc.7.4M5.07%$34.4M+218K+3.0%
Nantahala Capital Management, LLC6.9M4.74%$32.2M-2.6M-28%
Vanguard Capital Management LLC5.2M3.54%$24.0M-28K-0.5%
Paradigm Capital Management Inc4.6M3.12%$21.2M+482K+12%
State Street Corp4.4M3.02%$20.5M-1.2M-21%
Geode Capital Management, LLC3.1M2.16%$14.7M+4,312+0.1%
Renaissance Technologies LLC2.4M1.62%$11.0M-75K-3.1%
AQR Capital Management LLC2.3M1.59%$10.8M-141K-5.7%

Company events

All 77 company events

In 12 months: 1 director or officer change, 1 major agreement. Results releases and routine reports are left out.

FiledWhat happenedSource
29 Jul 2026Signed a major agreement8-K
16 Apr 2026Director or officer change8-K
16 Dec 2024Signed a major agreement8-K
4 Mar 2024Director or officer change8-K
22 Jan 2024Signed a major agreement; A major agreement endedSame filing: took on new debt8-K
5 Sep 2023Director or officer change8-K
5 Jul 2023Director or officer change8-K
20 Jun 2023Director or officer change8-K

Reported lobbying spend: $50K in Q3 2026, $50K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
15 Jul 2024NewArmory Hill Advocates (Formerly Known As Rawlson Policy Group)for MimedxLegislation and regulations impacting the delivery of wound management care to Medicare patients.Medicare/MedicaidFiling
1 Oct 2020NewBaker Donelson Bearman Caldwell & Berkowitzfor MimedxMedicare reimbursementMedicare/MedicaidFiling
30 Apr 2015EndedJeffrey J. Kimbell & Associates, Inc.for Mimedx Group, Inc.GENERAL HEALTH CARE ISSUES, ISSUES RELATED TO FDA, MEDICAL DEVICESHealth issuesFiling
2 Sep 2013NewJeffrey J. Kimbell & Associates, Inc.for Mimedx Group, Inc.General Healthcare and BiomaterialHealth issuesFiling
Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

26 Feb 2026confirmed

Confirmed across sources Filings + Financials and Short interest and volume

MiMedx (MDXG): reported revenue of $118.1M for the quarter ended 31 Dec 2025, 1.3× the same quarter last year, while it had 8.4M shares sold short in the 30 Apr 2026 report, 1.8× the same report last year. Two unrelated kinds of activity within 84 days.

  • Short interest and volume: Short interest spike, became public on 11 Feb 2026
  • Financials: Quarterly revenue change, became public on 26 Feb 2026
  • Short interest and volume: Short interest spike, became public on 26 Feb 2026
  • Short interest and volume: Short interest spike, became public on 11 Mar 2026
  • Short interest and volume: Short interest spike, became public on 11 Apr 2026
  • Short interest and volume: Short interest spike, became public on 25 Apr 2026
  • Financials: Quarterly revenue change, became public on 30 Apr 2026
  • Short interest and volume: Short interest spike, became public on 12 May 2026
2023-12-31: $86.8M2024-03-31: $84.7M2024-06-30: $87.2M2024-09-30: $84.1M2024-12-31: $92.9M2025-03-31: $88.2M2025-06-30: $98.6M2025-09-30: $113.7M2025-12-31: $118.1M
The quarter ended 31 Dec 2025 against the 8 quarters before it. this quarterearliernormal: $87.7M
See the evidence (8 changes)

Short interest and volume: Short interest spike became public on 11 Feb 2026

MiMedx had 7.1M shares sold short in the 30 Jan 2026 report, 1.8× the same report last year.

This period
7.1M (the 30 Jan 2026 report)
Normal report (median of 24 earlier)
4.8M
Typical spread (median absolute deviation)
274K
How far from its usual level
+4.9
Same report last year
3.9M
History used
2,954 days
2025-01-31: 3.9M2025-02-14: 3.7M2025-02-28: 4.1M2025-03-14: 4.2M2025-03-31: 4.7M2025-04-15: 4.8M2025-04-30: 4.8M2025-05-15: 5.3M2025-05-30: 5.2M2025-06-13: 5.0M2025-06-30: 5.3M2025-07-15: 5.5M2025-07-31: 5.0M2025-08-15: 5.0M2025-08-29: 5.0M2025-09-15: 4.8M2025-09-30: 4.7M2025-10-15: 4.8M2025-10-31: 4.5M2025-11-14: 4.7M2025-11-28: 4.4M2025-12-15: 4.6M2025-12-31: 5.4M2026-01-15: 6.3M2026-01-30: 7.1M
the 30 Jan 2026 report24 earlier reportsnormal: 4.8M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Financials: Quarterly revenue change became public on 26 Feb 2026

MiMedx reported revenue of $118.1M for the quarter ended 31 Dec 2025, 1.3× the same quarter last year.

This period
$118.1M (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
$87.7M
Typical spread (median absolute deviation)
$3.3M
How far from its usual level
+3.5
Same quarter last year
$92.9M
History used
3,562 days
2023-12-31: $86.8M2024-03-31: $84.7M2024-06-30: $87.2M2024-09-30: $84.1M2024-12-31: $92.9M2025-03-31: $88.2M2025-06-30: $98.6M2025-09-30: $113.7M2025-12-31: $118.1M
the quarter ended 31 Dec 20258 earlier quartersnormal: $87.7M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Short interest and volume: Short interest spike became public on 26 Feb 2026

MiMedx had 7.3M shares sold short in the 13 Feb 2026 report, 2.0× the same report last year.

This period
7.3M (the 13 Feb 2026 report)
Normal report (median of 24 earlier)
4.8M
Typical spread (median absolute deviation)
283K
How far from its usual level
+5.1
Same report last year
3.7M
History used
2,968 days
2025-02-14: 3.7M2025-02-28: 4.1M2025-03-14: 4.2M2025-03-31: 4.7M2025-04-15: 4.8M2025-04-30: 4.8M2025-05-15: 5.3M2025-05-30: 5.2M2025-06-13: 5.0M2025-06-30: 5.3M2025-07-15: 5.5M2025-07-31: 5.0M2025-08-15: 5.0M2025-08-29: 5.0M2025-09-15: 4.8M2025-09-30: 4.7M2025-10-15: 4.8M2025-10-31: 4.5M2025-11-14: 4.7M2025-11-28: 4.4M2025-12-15: 4.6M2025-12-31: 5.4M2026-01-15: 6.3M2026-01-30: 7.1M2026-02-13: 7.3M
the 13 Feb 2026 report24 earlier reportsnormal: 4.8M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 11 Mar 2026

MiMedx had 6.7M shares sold short in the 27 Feb 2026 report, 1.6× the same report last year.

This period
6.7M (the 27 Feb 2026 report)
Normal report (median of 24 earlier)
4.9M
Typical spread (median absolute deviation)
295K
How far from its usual level
+3.7
Same report last year
4.1M
History used
2,982 days
2025-02-28: 4.1M2025-03-14: 4.2M2025-03-31: 4.7M2025-04-15: 4.8M2025-04-30: 4.8M2025-05-15: 5.3M2025-05-30: 5.2M2025-06-13: 5.0M2025-06-30: 5.3M2025-07-15: 5.5M2025-07-31: 5.0M2025-08-15: 5.0M2025-08-29: 5.0M2025-09-15: 4.8M2025-09-30: 4.7M2025-10-15: 4.8M2025-10-31: 4.5M2025-11-14: 4.7M2025-11-28: 4.4M2025-12-15: 4.6M2025-12-31: 5.4M2026-01-15: 6.3M2026-01-30: 7.1M2026-02-13: 7.3M2026-02-27: 6.7M
the 27 Feb 2026 report24 earlier reportsnormal: 4.9M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 11 Apr 2026

MiMedx had 7.7M shares sold short in the 31 Mar 2026 report, 1.6× the same report last year.

This period
7.7M (the 31 Mar 2026 report)
Normal report (median of 24 earlier)
5.0M
Typical spread (median absolute deviation)
323K
How far from its usual level
+5.3
Same report last year
4.7M
History used
3,014 days
2025-03-31: 4.7M2025-04-15: 4.8M2025-04-30: 4.8M2025-05-15: 5.3M2025-05-30: 5.2M2025-06-13: 5.0M2025-06-30: 5.3M2025-07-15: 5.5M2025-07-31: 5.0M2025-08-15: 5.0M2025-08-29: 5.0M2025-09-15: 4.8M2025-09-30: 4.7M2025-10-15: 4.8M2025-10-31: 4.5M2025-11-14: 4.7M2025-11-28: 4.4M2025-12-15: 4.6M2025-12-31: 5.4M2026-01-15: 6.3M2026-01-30: 7.1M2026-02-13: 7.3M2026-02-27: 6.7M2026-03-13: 6.2M2026-03-31: 7.7M
the 31 Mar 2026 report24 earlier reportsnormal: 5.0M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 25 Apr 2026

MiMedx had 7.4M shares sold short in the 15 Apr 2026 report, 1.5× the same report last year.

This period
7.4M (the 15 Apr 2026 report)
Normal report (median of 24 earlier)
5.0M
Typical spread (median absolute deviation)
334K
How far from its usual level
+4.9
Same report last year
4.8M
History used
3,029 days
2025-04-15: 4.8M2025-04-30: 4.8M2025-05-15: 5.3M2025-05-30: 5.2M2025-06-13: 5.0M2025-06-30: 5.3M2025-07-15: 5.5M2025-07-31: 5.0M2025-08-15: 5.0M2025-08-29: 5.0M2025-09-15: 4.8M2025-09-30: 4.7M2025-10-15: 4.8M2025-10-31: 4.5M2025-11-14: 4.7M2025-11-28: 4.4M2025-12-15: 4.6M2025-12-31: 5.4M2026-01-15: 6.3M2026-01-30: 7.1M2026-02-13: 7.3M2026-02-27: 6.7M2026-03-13: 6.2M2026-03-31: 7.7M2026-04-15: 7.4M
the 15 Apr 2026 report24 earlier reportsnormal: 5.0M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Financials: Quarterly revenue change became public on 30 Apr 2026

MiMedx reported revenue of $59.0M for the quarter ended 31 Mar 2026, 33% below the same quarter last year.

This period
$59.0M (the quarter ended 31 Mar 2026)
Normal quarter (median of 8 earlier)
$90.6M
Typical spread (median absolute deviation)
$6.2M
How far from its usual level
-3.4
Same quarter last year
$88.2M
History used
3,652 days
2024-03-31: $84.7M2024-06-30: $87.2M2024-09-30: $84.1M2024-12-31: $92.9M2025-03-31: $88.2M2025-06-30: $98.6M2025-09-30: $113.7M2025-12-31: $118.1M2026-03-31: $59.0M
the quarter ended 31 Mar 20268 earlier quartersnormal: $90.6M

Fires when the period is at least 3.0 robust standard deviations away from the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Short interest and volume: Short interest spike became public on 12 May 2026

MiMedx had 8.4M shares sold short in the 30 Apr 2026 report, 1.8× the same report last year.

This period
8.4M (the 30 Apr 2026 report)
Normal report (median of 24 earlier)
5.1M
Typical spread (median absolute deviation)
397K
How far from its usual level
+5.6
Same report last year
4.8M
History used
3,044 days
2025-04-30: 4.8M2025-05-15: 5.3M2025-05-30: 5.2M2025-06-13: 5.0M2025-06-30: 5.3M2025-07-15: 5.5M2025-07-31: 5.0M2025-08-15: 5.0M2025-08-29: 5.0M2025-09-15: 4.8M2025-09-30: 4.7M2025-10-15: 4.8M2025-10-31: 4.5M2025-11-14: 4.7M2025-11-28: 4.4M2025-12-15: 4.6M2025-12-31: 5.4M2026-01-15: 6.3M2026-01-30: 7.1M2026-02-13: 7.3M2026-02-27: 6.7M2026-03-13: 6.2M2026-03-31: 7.7M2026-04-15: 7.4M2026-04-30: 8.4M
the 30 Apr 2026 report24 earlier reportsnormal: 5.1M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

16 Feb 2021confirmed

Confirmed across sources Institutional holdings and Lobbying

MiMedx (MDXG): lobbying on a new issue, while it saw 75 13F filers open a new position in the quarter ended 31 Dec 2020, against none in the same quarter last year. Two unrelated kinds of activity within 26 days.

  • Lobbying: Lobbying on a new issue, became public on 21 Jan 2021
  • Institutional holdings: Many funds opening a new position, became public on 16 Feb 2021
2018-12-31: 42019-03-31: 12019-06-30: 02019-09-30: 32019-12-31: 02020-03-31: 22020-06-30: 12020-09-30: 22020-12-31: 75
The quarter ended 31 Dec 2020 against the 8 quarters before it. this quarterearliernormal: 1.5
See the evidence (2 changes)

Lobbying: Lobbying on a new issue became public on 21 Jan 2021

MiMedx lobbying on a new issue.

New
['MMM']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
12774282

Institutional holdings: Many funds opening a new position became public on 16 Feb 2021

MiMedx saw 75 13F filers open a new position in the quarter ended 31 Dec 2020, against none in the same quarter last year.

This period
75 (the quarter ended 31 Dec 2020)
Normal quarter (median of 8 earlier)
1.5
Typical spread (median absolute deviation)
1
How far from its usual level
+24.5
Same quarter last year
0
History used
2,649 days
2018-12-31: 42019-03-31: 12019-06-30: 02019-09-30: 32019-12-31: 02020-03-31: 22020-06-30: 12020-09-30: 22020-12-31: 75
the quarter ended 31 Dec 20208 earlier quartersnormal: 1.5

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 12 May 2026Short interest and volume change

    had 8.4M shares sold short in the 30 Apr 2026 report, 1.8× the same report last year.

    Same report last year: 4.8M; its normal report is 5.1M.

    See the evidence
    This period
    8.4M (the 30 Apr 2026 report)
    Normal report (median of 24 earlier)
    5.1M
    Typical spread (median absolute deviation)
    397K
    How far from its usual level
    +5.6
    Same report last year
    4.8M
    History used
    3,044 days
    2025-04-30: 4.8M2025-05-15: 5.3M2025-05-30: 5.2M2025-06-13: 5.0M2025-06-30: 5.3M2025-07-15: 5.5M2025-07-31: 5.0M2025-08-15: 5.0M2025-08-29: 5.0M2025-09-15: 4.8M2025-09-30: 4.7M2025-10-15: 4.8M2025-10-31: 4.5M2025-11-14: 4.7M2025-11-28: 4.4M2025-12-15: 4.6M2025-12-31: 5.4M2026-01-15: 6.3M2026-01-30: 7.1M2026-02-13: 7.3M2026-02-27: 6.7M2026-03-13: 6.2M2026-03-31: 7.7M2026-04-15: 7.4M2026-04-30: 8.4M
    the 30 Apr 2026 report24 earlier reportsnormal: 5.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  2. 30 Apr 2026Financials change

    reported revenue of $59.0M for the quarter ended 31 Mar 2026, 33% below the same quarter last year.

    Same quarter last year: $88.2M; its normal quarter is $90.6M.

    See the evidence
    This period
    $59.0M (the quarter ended 31 Mar 2026)
    Normal quarter (median of 8 earlier)
    $90.6M
    Typical spread (median absolute deviation)
    $6.2M
    How far from its usual level
    -3.4
    Same quarter last year
    $88.2M
    History used
    3,652 days
    2024-03-31: $84.7M2024-06-30: $87.2M2024-09-30: $84.1M2024-12-31: $92.9M2025-03-31: $88.2M2025-06-30: $98.6M2025-09-30: $113.7M2025-12-31: $118.1M2026-03-31: $59.0M
    the quarter ended 31 Mar 20268 earlier quartersnormal: $90.6M

    Fires when the period is at least 3.0 robust standard deviations away from the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  3. 25 Apr 2026Short interest and volume change

    had 7.4M shares sold short in the 15 Apr 2026 report, 1.5× the same report last year.

    Same report last year: 4.8M; its normal report is 5.0M.

    See the evidence
    This period
    7.4M (the 15 Apr 2026 report)
    Normal report (median of 24 earlier)
    5.0M
    Typical spread (median absolute deviation)
    334K
    How far from its usual level
    +4.9
    Same report last year
    4.8M
    History used
    3,029 days
    2025-04-15: 4.8M2025-04-30: 4.8M2025-05-15: 5.3M2025-05-30: 5.2M2025-06-13: 5.0M2025-06-30: 5.3M2025-07-15: 5.5M2025-07-31: 5.0M2025-08-15: 5.0M2025-08-29: 5.0M2025-09-15: 4.8M2025-09-30: 4.7M2025-10-15: 4.8M2025-10-31: 4.5M2025-11-14: 4.7M2025-11-28: 4.4M2025-12-15: 4.6M2025-12-31: 5.4M2026-01-15: 6.3M2026-01-30: 7.1M2026-02-13: 7.3M2026-02-27: 6.7M2026-03-13: 6.2M2026-03-31: 7.7M2026-04-15: 7.4M
    the 15 Apr 2026 report24 earlier reportsnormal: 5.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  4. 16 Apr 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  5. 16 Apr 2026Filings record

    Director or officer change

  6. 11 Apr 2026Short interest and volume change

    had 7.7M shares sold short in the 31 Mar 2026 report, 1.6× the same report last year.

    Same report last year: 4.7M; its normal report is 5.0M.

    See the evidence
    This period
    7.7M (the 31 Mar 2026 report)
    Normal report (median of 24 earlier)
    5.0M
    Typical spread (median absolute deviation)
    323K
    How far from its usual level
    +5.3
    Same report last year
    4.7M
    History used
    3,014 days
    2025-03-31: 4.7M2025-04-15: 4.8M2025-04-30: 4.8M2025-05-15: 5.3M2025-05-30: 5.2M2025-06-13: 5.0M2025-06-30: 5.3M2025-07-15: 5.5M2025-07-31: 5.0M2025-08-15: 5.0M2025-08-29: 5.0M2025-09-15: 4.8M2025-09-30: 4.7M2025-10-15: 4.8M2025-10-31: 4.5M2025-11-14: 4.7M2025-11-28: 4.4M2025-12-15: 4.6M2025-12-31: 5.4M2026-01-15: 6.3M2026-01-30: 7.1M2026-02-13: 7.3M2026-02-27: 6.7M2026-03-13: 6.2M2026-03-31: 7.7M
    the 31 Mar 2026 report24 earlier reportsnormal: 5.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  7. 11 Mar 2026Short interest and volume change

    had 6.7M shares sold short in the 27 Feb 2026 report, 1.6× the same report last year.

    Same report last year: 4.1M; its normal report is 4.9M.

    See the evidence
    This period
    6.7M (the 27 Feb 2026 report)
    Normal report (median of 24 earlier)
    4.9M
    Typical spread (median absolute deviation)
    295K
    How far from its usual level
    +3.7
    Same report last year
    4.1M
    History used
    2,982 days
    2025-02-28: 4.1M2025-03-14: 4.2M2025-03-31: 4.7M2025-04-15: 4.8M2025-04-30: 4.8M2025-05-15: 5.3M2025-05-30: 5.2M2025-06-13: 5.0M2025-06-30: 5.3M2025-07-15: 5.5M2025-07-31: 5.0M2025-08-15: 5.0M2025-08-29: 5.0M2025-09-15: 4.8M2025-09-30: 4.7M2025-10-15: 4.8M2025-10-31: 4.5M2025-11-14: 4.7M2025-11-28: 4.4M2025-12-15: 4.6M2025-12-31: 5.4M2026-01-15: 6.3M2026-01-30: 7.1M2026-02-13: 7.3M2026-02-27: 6.7M
    the 27 Feb 2026 report24 earlier reportsnormal: 4.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  8. 26 Feb 2026several at once

    reported revenue of $118.1M for the quarter ended 31 Dec 2025, 1.3× the same quarter last year, while it had 8.4M shares sold short in the 30 Apr 2026 report, 1.8× the same report last year. Two unrelated kinds of activity within 84 days.

    See the evidence (8 changes)

    Short interest and volume: Short interest spike became public on 11 Feb 2026

    MiMedx had 7.1M shares sold short in the 30 Jan 2026 report, 1.8× the same report last year.

    This period
    7.1M (the 30 Jan 2026 report)
    Normal report (median of 24 earlier)
    4.8M
    Typical spread (median absolute deviation)
    274K
    How far from its usual level
    +4.9
    Same report last year
    3.9M
    History used
    2,954 days
    2025-01-31: 3.9M2025-02-14: 3.7M2025-02-28: 4.1M2025-03-14: 4.2M2025-03-31: 4.7M2025-04-15: 4.8M2025-04-30: 4.8M2025-05-15: 5.3M2025-05-30: 5.2M2025-06-13: 5.0M2025-06-30: 5.3M2025-07-15: 5.5M2025-07-31: 5.0M2025-08-15: 5.0M2025-08-29: 5.0M2025-09-15: 4.8M2025-09-30: 4.7M2025-10-15: 4.8M2025-10-31: 4.5M2025-11-14: 4.7M2025-11-28: 4.4M2025-12-15: 4.6M2025-12-31: 5.4M2026-01-15: 6.3M2026-01-30: 7.1M
    the 30 Jan 2026 report24 earlier reportsnormal: 4.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Financials: Quarterly revenue change became public on 26 Feb 2026

    MiMedx reported revenue of $118.1M for the quarter ended 31 Dec 2025, 1.3× the same quarter last year.

    This period
    $118.1M (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    $87.7M
    Typical spread (median absolute deviation)
    $3.3M
    How far from its usual level
    +3.5
    Same quarter last year
    $92.9M
    History used
    3,562 days
    2023-12-31: $86.8M2024-03-31: $84.7M2024-06-30: $87.2M2024-09-30: $84.1M2024-12-31: $92.9M2025-03-31: $88.2M2025-06-30: $98.6M2025-09-30: $113.7M2025-12-31: $118.1M
    the quarter ended 31 Dec 20258 earlier quartersnormal: $87.7M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Short interest and volume: Short interest spike became public on 26 Feb 2026

    MiMedx had 7.3M shares sold short in the 13 Feb 2026 report, 2.0× the same report last year.

    This period
    7.3M (the 13 Feb 2026 report)
    Normal report (median of 24 earlier)
    4.8M
    Typical spread (median absolute deviation)
    283K
    How far from its usual level
    +5.1
    Same report last year
    3.7M
    History used
    2,968 days
    2025-02-14: 3.7M2025-02-28: 4.1M2025-03-14: 4.2M2025-03-31: 4.7M2025-04-15: 4.8M2025-04-30: 4.8M2025-05-15: 5.3M2025-05-30: 5.2M2025-06-13: 5.0M2025-06-30: 5.3M2025-07-15: 5.5M2025-07-31: 5.0M2025-08-15: 5.0M2025-08-29: 5.0M2025-09-15: 4.8M2025-09-30: 4.7M2025-10-15: 4.8M2025-10-31: 4.5M2025-11-14: 4.7M2025-11-28: 4.4M2025-12-15: 4.6M2025-12-31: 5.4M2026-01-15: 6.3M2026-01-30: 7.1M2026-02-13: 7.3M
    the 13 Feb 2026 report24 earlier reportsnormal: 4.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 11 Mar 2026

    MiMedx had 6.7M shares sold short in the 27 Feb 2026 report, 1.6× the same report last year.

    This period
    6.7M (the 27 Feb 2026 report)
    Normal report (median of 24 earlier)
    4.9M
    Typical spread (median absolute deviation)
    295K
    How far from its usual level
    +3.7
    Same report last year
    4.1M
    History used
    2,982 days
    2025-02-28: 4.1M2025-03-14: 4.2M2025-03-31: 4.7M2025-04-15: 4.8M2025-04-30: 4.8M2025-05-15: 5.3M2025-05-30: 5.2M2025-06-13: 5.0M2025-06-30: 5.3M2025-07-15: 5.5M2025-07-31: 5.0M2025-08-15: 5.0M2025-08-29: 5.0M2025-09-15: 4.8M2025-09-30: 4.7M2025-10-15: 4.8M2025-10-31: 4.5M2025-11-14: 4.7M2025-11-28: 4.4M2025-12-15: 4.6M2025-12-31: 5.4M2026-01-15: 6.3M2026-01-30: 7.1M2026-02-13: 7.3M2026-02-27: 6.7M
    the 27 Feb 2026 report24 earlier reportsnormal: 4.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 11 Apr 2026

    MiMedx had 7.7M shares sold short in the 31 Mar 2026 report, 1.6× the same report last year.

    This period
    7.7M (the 31 Mar 2026 report)
    Normal report (median of 24 earlier)
    5.0M
    Typical spread (median absolute deviation)
    323K
    How far from its usual level
    +5.3
    Same report last year
    4.7M
    History used
    3,014 days
    2025-03-31: 4.7M2025-04-15: 4.8M2025-04-30: 4.8M2025-05-15: 5.3M2025-05-30: 5.2M2025-06-13: 5.0M2025-06-30: 5.3M2025-07-15: 5.5M2025-07-31: 5.0M2025-08-15: 5.0M2025-08-29: 5.0M2025-09-15: 4.8M2025-09-30: 4.7M2025-10-15: 4.8M2025-10-31: 4.5M2025-11-14: 4.7M2025-11-28: 4.4M2025-12-15: 4.6M2025-12-31: 5.4M2026-01-15: 6.3M2026-01-30: 7.1M2026-02-13: 7.3M2026-02-27: 6.7M2026-03-13: 6.2M2026-03-31: 7.7M
    the 31 Mar 2026 report24 earlier reportsnormal: 5.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 25 Apr 2026

    MiMedx had 7.4M shares sold short in the 15 Apr 2026 report, 1.5× the same report last year.

    This period
    7.4M (the 15 Apr 2026 report)
    Normal report (median of 24 earlier)
    5.0M
    Typical spread (median absolute deviation)
    334K
    How far from its usual level
    +4.9
    Same report last year
    4.8M
    History used
    3,029 days
    2025-04-15: 4.8M2025-04-30: 4.8M2025-05-15: 5.3M2025-05-30: 5.2M2025-06-13: 5.0M2025-06-30: 5.3M2025-07-15: 5.5M2025-07-31: 5.0M2025-08-15: 5.0M2025-08-29: 5.0M2025-09-15: 4.8M2025-09-30: 4.7M2025-10-15: 4.8M2025-10-31: 4.5M2025-11-14: 4.7M2025-11-28: 4.4M2025-12-15: 4.6M2025-12-31: 5.4M2026-01-15: 6.3M2026-01-30: 7.1M2026-02-13: 7.3M2026-02-27: 6.7M2026-03-13: 6.2M2026-03-31: 7.7M2026-04-15: 7.4M
    the 15 Apr 2026 report24 earlier reportsnormal: 5.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Financials: Quarterly revenue change became public on 30 Apr 2026

    MiMedx reported revenue of $59.0M for the quarter ended 31 Mar 2026, 33% below the same quarter last year.

    This period
    $59.0M (the quarter ended 31 Mar 2026)
    Normal quarter (median of 8 earlier)
    $90.6M
    Typical spread (median absolute deviation)
    $6.2M
    How far from its usual level
    -3.4
    Same quarter last year
    $88.2M
    History used
    3,652 days
    2024-03-31: $84.7M2024-06-30: $87.2M2024-09-30: $84.1M2024-12-31: $92.9M2025-03-31: $88.2M2025-06-30: $98.6M2025-09-30: $113.7M2025-12-31: $118.1M2026-03-31: $59.0M
    the quarter ended 31 Mar 20268 earlier quartersnormal: $90.6M

    Fires when the period is at least 3.0 robust standard deviations away from the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Short interest and volume: Short interest spike became public on 12 May 2026

    MiMedx had 8.4M shares sold short in the 30 Apr 2026 report, 1.8× the same report last year.

    This period
    8.4M (the 30 Apr 2026 report)
    Normal report (median of 24 earlier)
    5.1M
    Typical spread (median absolute deviation)
    397K
    How far from its usual level
    +5.6
    Same report last year
    4.8M
    History used
    3,044 days
    2025-04-30: 4.8M2025-05-15: 5.3M2025-05-30: 5.2M2025-06-13: 5.0M2025-06-30: 5.3M2025-07-15: 5.5M2025-07-31: 5.0M2025-08-15: 5.0M2025-08-29: 5.0M2025-09-15: 4.8M2025-09-30: 4.7M2025-10-15: 4.8M2025-10-31: 4.5M2025-11-14: 4.7M2025-11-28: 4.4M2025-12-15: 4.6M2025-12-31: 5.4M2026-01-15: 6.3M2026-01-30: 7.1M2026-02-13: 7.3M2026-02-27: 6.7M2026-03-13: 6.2M2026-03-31: 7.7M2026-04-15: 7.4M2026-04-30: 8.4M
    the 30 Apr 2026 report24 earlier reportsnormal: 5.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  9. 26 Feb 2026Short interest and volume change

    had 7.3M shares sold short in the 13 Feb 2026 report, 2.0× the same report last year.

    Same report last year: 3.7M; its normal report is 4.8M.

    See the evidence
    This period
    7.3M (the 13 Feb 2026 report)
    Normal report (median of 24 earlier)
    4.8M
    Typical spread (median absolute deviation)
    283K
    How far from its usual level
    +5.1
    Same report last year
    3.7M
    History used
    2,968 days
    2025-02-14: 3.7M2025-02-28: 4.1M2025-03-14: 4.2M2025-03-31: 4.7M2025-04-15: 4.8M2025-04-30: 4.8M2025-05-15: 5.3M2025-05-30: 5.2M2025-06-13: 5.0M2025-06-30: 5.3M2025-07-15: 5.5M2025-07-31: 5.0M2025-08-15: 5.0M2025-08-29: 5.0M2025-09-15: 4.8M2025-09-30: 4.7M2025-10-15: 4.8M2025-10-31: 4.5M2025-11-14: 4.7M2025-11-28: 4.4M2025-12-15: 4.6M2025-12-31: 5.4M2026-01-15: 6.3M2026-01-30: 7.1M2026-02-13: 7.3M
    the 13 Feb 2026 report24 earlier reportsnormal: 4.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  10. 26 Feb 2026Financials change

    reported revenue of $118.1M for the quarter ended 31 Dec 2025, 1.3× the same quarter last year.

    Same quarter last year: $92.9M; its normal quarter is $87.7M.

    See the evidence
    This period
    $118.1M (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    $87.7M
    Typical spread (median absolute deviation)
    $3.3M
    How far from its usual level
    +3.5
    Same quarter last year
    $92.9M
    History used
    3,562 days
    2023-12-31: $86.8M2024-03-31: $84.7M2024-06-30: $87.2M2024-09-30: $84.1M2024-12-31: $92.9M2025-03-31: $88.2M2025-06-30: $98.6M2025-09-30: $113.7M2025-12-31: $118.1M
    the quarter ended 31 Dec 20258 earlier quartersnormal: $87.7M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  11. 11 Feb 2026Short interest and volume change

    had 7.1M shares sold short in the 30 Jan 2026 report, 1.8× the same report last year.

    Same report last year: 3.9M; its normal report is 4.8M.

    See the evidence
    This period
    7.1M (the 30 Jan 2026 report)
    Normal report (median of 24 earlier)
    4.8M
    Typical spread (median absolute deviation)
    274K
    How far from its usual level
    +4.9
    Same report last year
    3.9M
    History used
    2,954 days
    2025-01-31: 3.9M2025-02-14: 3.7M2025-02-28: 4.1M2025-03-14: 4.2M2025-03-31: 4.7M2025-04-15: 4.8M2025-04-30: 4.8M2025-05-15: 5.3M2025-05-30: 5.2M2025-06-13: 5.0M2025-06-30: 5.3M2025-07-15: 5.5M2025-07-31: 5.0M2025-08-15: 5.0M2025-08-29: 5.0M2025-09-15: 4.8M2025-09-30: 4.7M2025-10-15: 4.8M2025-10-31: 4.5M2025-11-14: 4.7M2025-11-28: 4.4M2025-12-15: 4.6M2025-12-31: 5.4M2026-01-15: 6.3M2026-01-30: 7.1M
    the 30 Jan 2026 report24 earlier reportsnormal: 4.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  12. 30 Oct 2025Financials change

    reported revenue of $113.7M for the quarter ended 30 Sep 2025, 1.4× the same quarter last year.

    Same quarter last year: $84.1M; its normal quarter is $87.0M.

    See the evidence
    This period
    $113.7M (the quarter ended 30 Sep 2025)
    Normal quarter (median of 8 earlier)
    $87.0M
    Typical spread (median absolute deviation)
    $2.6M
    How far from its usual level
    +3.1
    Same quarter last year
    $84.1M
    History used
    3,470 days
    2023-09-30: $81.7M2023-12-31: $86.8M2024-03-31: $84.7M2024-06-30: $87.2M2024-09-30: $84.1M2024-12-31: $92.9M2025-03-31: $88.2M2025-06-30: $98.6M2025-09-30: $113.7M
    the quarter ended 30 Sep 20258 earlier quartersnormal: $87.0M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  13. 6 May 2025Insiders record

    Capper Joseph H (Chief Executive Officer) bought 200,000 shares of MDXG ($1.3M) (dated 5 May 2025)

  14. 24 Jul 2024Lobbying record

    MIMEDX: new lobbying registration (ARMORY HILL ADVOCATES (FORMERLY KNOWN AS RAWLSON POLICY GROUP)) (dated 15 Jul 2024)

  15. 27 Mar 2024Short interest and volume change

    had 5.5M shares sold short in the 15 Mar 2024 report, 1.7× the same report last year.

    Same report last year: 3.3M; its normal report is 3.5M.

    See the evidence
    This period
    5.5M (the 15 Mar 2024 report)
    Normal report (median of 24 earlier)
    3.5M
    Typical spread (median absolute deviation)
    353K
    How far from its usual level
    +3.8
    Same report last year
    3.3M
    History used
    2,268 days
    2023-03-15: 3.3M2023-03-31: 3.4M2023-04-14: 3.2M2023-04-28: 3.4M2023-05-15: 3.5M2023-05-31: 3.5M2023-06-15: 3.4M2023-06-30: 3.3M2023-07-14: 3.4M2023-07-31: 3.4M2023-08-15: 3.2M2023-08-31: 3.3M2023-09-15: 3.6M2023-09-29: 4.6M2023-10-13: 4.7M2023-10-31: 4.7M2023-11-15: 4.1M2023-11-30: 4.3M2023-12-15: 4.2M2023-12-29: 4.0M2024-01-12: 4.3M2024-01-31: 4.5M2024-02-15: 4.9M2024-02-29: 5.3M2024-03-15: 5.5M
    the 15 Mar 2024 report24 earlier reportsnormal: 3.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  16. 12 Mar 2024Short interest and volume change

    had 5.3M shares sold short in the 29 Feb 2024 report, 1.7× the same report last year.

    Same report last year: 3.2M; its normal report is 3.5M.

    See the evidence
    This period
    5.3M (the 29 Feb 2024 report)
    Normal report (median of 24 earlier)
    3.5M
    Typical spread (median absolute deviation)
    292K
    How far from its usual level
    +4.2
    Same report last year
    3.2M
    History used
    2,253 days
    2023-02-28: 3.2M2023-03-15: 3.3M2023-03-31: 3.4M2023-04-14: 3.2M2023-04-28: 3.4M2023-05-15: 3.5M2023-05-31: 3.5M2023-06-15: 3.4M2023-06-30: 3.3M2023-07-14: 3.4M2023-07-31: 3.4M2023-08-15: 3.2M2023-08-31: 3.3M2023-09-15: 3.6M2023-09-29: 4.6M2023-10-13: 4.7M2023-10-31: 4.7M2023-11-15: 4.1M2023-11-30: 4.3M2023-12-15: 4.2M2023-12-29: 4.0M2024-01-12: 4.3M2024-01-31: 4.5M2024-02-15: 4.9M2024-02-29: 5.3M
    the 29 Feb 2024 report24 earlier reportsnormal: 3.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  17. 4 Mar 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  18. 4 Mar 2024Filings record

    Director or officer change

  19. 28 Feb 2024Short interest and volume change

    had 4.9M shares sold short in the 15 Feb 2024 report, 1.6× the same report last year.

    Same report last year: 3.1M; its normal report is 3.4M.

    See the evidence
    This period
    4.9M (the 15 Feb 2024 report)
    Normal report (median of 24 earlier)
    3.4M
    Typical spread (median absolute deviation)
    243K
    How far from its usual level
    +4.0
    Same report last year
    3.1M
    History used
    2,239 days
    2023-02-15: 3.1M2023-02-28: 3.2M2023-03-15: 3.3M2023-03-31: 3.4M2023-04-14: 3.2M2023-04-28: 3.4M2023-05-15: 3.5M2023-05-31: 3.5M2023-06-15: 3.4M2023-06-30: 3.3M2023-07-14: 3.4M2023-07-31: 3.4M2023-08-15: 3.2M2023-08-31: 3.3M2023-09-15: 3.6M2023-09-29: 4.6M2023-10-13: 4.7M2023-10-31: 4.7M2023-11-15: 4.1M2023-11-30: 4.3M2023-12-15: 4.2M2023-12-29: 4.0M2024-01-12: 4.3M2024-01-31: 4.5M2024-02-15: 4.9M
    the 15 Feb 2024 report24 earlier reportsnormal: 3.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  20. 22 Jan 2024Filings record

    A major agreement ended

  21. 23 Nov 2023Insiders record

    DOUG RICE (Chief Financial Officer) bought 5,000 shares of MDXG ($35,800) (dated 22 Nov 2023)

  22. 10 Nov 2023Short interest and volume change

    had 4.7M shares sold short in the 31 Oct 2023 report, 1.3× the same report last year.

    Same report last year: 3.7M; its normal report is 3.3M.

    See the evidence
    This period
    4.7M (the 31 Oct 2023 report)
    Normal report (median of 24 earlier)
    3.3M
    Typical spread (median absolute deviation)
    162K
    How far from its usual level
    +4.0
    Same report last year
    3.7M
    History used
    2,132 days
    2022-10-31: 3.7M2022-11-15: 3.4M2022-11-30: 3.2M2022-12-15: 3.0M2022-12-30: 3.0M2023-01-13: 2.9M2023-01-31: 2.9M2023-02-15: 3.1M2023-02-28: 3.2M2023-03-15: 3.3M2023-03-31: 3.4M2023-04-14: 3.2M2023-04-28: 3.4M2023-05-15: 3.5M2023-05-31: 3.5M2023-06-15: 3.4M2023-06-30: 3.3M2023-07-14: 3.4M2023-07-31: 3.4M2023-08-15: 3.2M2023-08-31: 3.3M2023-09-15: 3.6M2023-09-29: 4.6M2023-10-13: 4.7M2023-10-31: 4.7M
    the 31 Oct 2023 report24 earlier reportsnormal: 3.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  23. 25 Oct 2023Short interest and volume change

    had 4.7M shares sold short in the 13 Oct 2023 report, 1.2× the same report last year.

    Same report last year: 3.8M; its normal report is 3.3M.

    See the evidence
    This period
    4.7M (the 13 Oct 2023 report)
    Normal report (median of 24 earlier)
    3.3M
    Typical spread (median absolute deviation)
    162K
    How far from its usual level
    +4.1
    Same report last year
    3.8M
    History used
    2,114 days
    2022-10-14: 3.8M2022-10-31: 3.7M2022-11-15: 3.4M2022-11-30: 3.2M2022-12-15: 3.0M2022-12-30: 3.0M2023-01-13: 2.9M2023-01-31: 2.9M2023-02-15: 3.1M2023-02-28: 3.2M2023-03-15: 3.3M2023-03-31: 3.4M2023-04-14: 3.2M2023-04-28: 3.4M2023-05-15: 3.5M2023-05-31: 3.5M2023-06-15: 3.4M2023-06-30: 3.3M2023-07-14: 3.4M2023-07-31: 3.4M2023-08-15: 3.2M2023-08-31: 3.3M2023-09-15: 3.6M2023-09-29: 4.6M2023-10-13: 4.7M
    the 13 Oct 2023 report24 earlier reportsnormal: 3.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  24. 12 Oct 2023Short interest and volume change

    had 4.6M shares sold short in the 29 Sep 2023 report, 1.1× the same report last year.

    Same report last year: 4.0M; its normal report is 3.3M.

    See the evidence
    This period
    4.6M (the 29 Sep 2023 report)
    Normal report (median of 24 earlier)
    3.3M
    Typical spread (median absolute deviation)
    162K
    How far from its usual level
    +3.9
    Same report last year
    4.0M
    History used
    2,100 days
    2022-09-30: 4.0M2022-10-14: 3.8M2022-10-31: 3.7M2022-11-15: 3.4M2022-11-30: 3.2M2022-12-15: 3.0M2022-12-30: 3.0M2023-01-13: 2.9M2023-01-31: 2.9M2023-02-15: 3.1M2023-02-28: 3.2M2023-03-15: 3.3M2023-03-31: 3.4M2023-04-14: 3.2M2023-04-28: 3.4M2023-05-15: 3.5M2023-05-31: 3.5M2023-06-15: 3.4M2023-06-30: 3.3M2023-07-14: 3.4M2023-07-31: 3.4M2023-08-15: 3.2M2023-08-31: 3.3M2023-09-15: 3.6M2023-09-29: 4.6M
    the 29 Sep 2023 report24 earlier reportsnormal: 3.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  25. 5 Sep 2023Filings record

    Director or officer change

  26. 5 Jul 2023Filings record

    Director or officer change

  27. 27 Jun 2023Insiders record

    Capper Joseph H (Chief Executive Officer) bought 100,000 shares of MDXG ($640,144) (dated 26 Jun 2023)

  28. 20 Jun 2023Filings record

    Director or officer change

  29. 14 Jun 2023Filings record

    Director or officer change

  30. 24 Mar 2023Filings record

    Director or officer change

  31. 30 Jan 2023Filings record

    Director or officer change

  32. 3 Jan 2023Filings record

    Director or officer change

  33. 16 Dec 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  34. 16 Dec 2022Filings record

    Director or officer change

  35. 16 Sep 2022Filings record

    Director or officer change

  36. 6 Sep 2022Filings record

    Director or officer change

  37. 13 Jun 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  38. 13 Jun 2022Filings record

    Director or officer change

  39. 15 Nov 2021Institutional holdings change

    saw 27 13F filers open a new position in the quarter ended 30 Sep 2021, 14× the same quarter last year.

    Same quarter last year: 2; its normal quarter is 2.5.

    See the evidence
    This period
    27 (the quarter ended 30 Sep 2021)
    Normal quarter (median of 8 earlier)
    2.5
    Typical spread (median absolute deviation)
    2
    How far from its usual level
    +8.2
    Same quarter last year
    2
    History used
    2,922 days
    2019-09-30: 32019-12-31: 02020-03-31: 22020-06-30: 12020-09-30: 22020-12-31: 752021-03-31: 192021-06-30: 422021-09-30: 27
    the quarter ended 30 Sep 20218 earlier quartersnormal: 2.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  40. 16 Aug 2021Institutional holdings change

    saw 42 13F filers open a new position in the quarter ended 30 Jun 2021, 42× the same quarter last year.

    Same quarter last year: 1; its normal quarter is 2.

    See the evidence
    This period
    42 (the quarter ended 30 Jun 2021)
    Normal quarter (median of 8 earlier)
    2
    Typical spread (median absolute deviation)
    1.5
    How far from its usual level
    +13.3
    Same quarter last year
    1
    History used
    2,830 days
    2019-06-30: 02019-09-30: 32019-12-31: 02020-03-31: 22020-06-30: 12020-09-30: 22020-12-31: 752021-03-31: 192021-06-30: 42
    the quarter ended 30 Jun 20218 earlier quartersnormal: 2

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

Showing the newest 40 of 104 entries; narrow the window or the kind of data to see older ones.

Not listed: 198 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001376339
Ticker
MDXG
Domain
mimedx.com
Employer name
MiMedx Group, Inc. (1 unverified)
Hq location
GA|MARIETTA|30062 (1 unverified)
Lobbying client
mimedx, mimedx group
Name
Alynx, Co., Company, MiMedx Group, Inc, MiMedx Japan, Godo Kaisha and 3 more
Uei
LHMTCHSJTFL3
Wikipedia
MiMedx
  • DOL H-1B labor condition applications and PERM certifications25 data points14 Jun 2021 to 7 Apr 2025
  • Federal lobbying disclosures (LDA)4 records, 96 data points2 Sep 2013 to 30 Sep 2026
  • SEC Form 13F institutional holdings481 data points30 Jun 2013 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)197 records11 Jan 2016 to 28 Oct 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)1027 data points31 Dec 2009 to 22 Oct 2026
  • SEC Form 4 insider transactions72 records, 192 data points12 May 2016 to 10 Nov 2025
  • FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)3178 data points1 Aug 2018 to 20 Nov 2026
  • USASpending.gov federal awards1746 data points14 Mar 2011 to 12 Feb 2025
  • Wikipedia pageviews11 data points11 Nov 2026 to 21 Nov 2026